Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Subcutaneous Bimekizumab in Healthy Subjects
NCT05028127Phase 1Completed
- Sponsor
- UCB
- Start
- Mar 2016
- Primary completion
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bimekizumab in plaque psoriasis (2 arms), sponsored by UCB. Primary endpoints: Number of Adverse Events including injection site reactions and systemic injection reactions and Relative Bioavailability (BA) of Bimekizumab. Started Mar 2016; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05028127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028127.